Glen Lawrence

Glen Lawrence is a retired Executive Director of SMP Product Development and co-founder of the Small Molecule Pharmaceutics group at Amgen, where they expanded the team from two to 55 staff members. Glen led the development of Sensipar and served as the Global CMC representative to international regulatory agencies, successfully defending CTD filings. Currently, Glen is a Principal Consultant at GLEN Pharmaceutical Consulting Services, providing expertise in CMC challenges for drug product development. Glen holds a Ph.D. in Industrial & Physical Pharmacy from Purdue University and a B.S. in Chemistry from Illinois State University.